Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C5H7NO4S |
Molar mass | 177.17 g·mol−1 |
3D model ( JSmol) | |
|
Cimlanod (development codes CXL-1427 and BMS-986231) is an experimental drug for the treatment of acute decompensated heart failure. It was discovered by Cardioxyl Pharmaceuticals, which was acquired by Bristol-Myers Squibb. It is a precursor of nitroxyl. [1]
Cimlanod is a prodrug of CXL-1020. [2]
A preliminary study showed efficacy in patients with class III and IV heart failure. [3] A phase II clinical trial was completed in 2016. [4]
Alternative Names: BMS-986231; CXL 1427; HNO Donor